Cited by 153Telomeres, Telomerase, and SenescenceCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index; 9 of the 159 sources its claims cite were checked for support.

COVID-19 and cellular senescence

Open access

Abstract

The clinical severity of coronavirus disease 2019 (COVID-19) is largely determined by host factors. Recent advances point to cellular senescence, an ageing-related switch in cellular state, as a critical regulator of SARS-CoV-2-evoked hyperinflammation. SARS-CoV-2, like other viruses, can induce senescence and exacerbates the senescence-associated secretory phenotype (SASP), which is comprised largely of pro-inflammatory, extracellular matrix-degrading, complement-activating and pro-coagulatory factors secreted by senescent cells. These effects are enhanced in elderly individuals who have an increased proportion of pre-existing senescent cells in their tissues. SASP factors can contribute to a 'cytokine storm', tissue-destructive immune cell infiltration, endothelialitis (endotheliitis), fibrosis and microthrombosis. SASP-driven spreading of cellular senescence uncouples tissue injury from direct SARS-CoV-2-inflicted cellular damage in a paracrine fashion and can further amplify the SASP by increasing the burden of senescent cells. Preclinical and early clinical studies indicate that targeted elimination of senescent cells may offer a novel therapeutic opportunity to attenuate clinical deterioration in COVID-19 and improve resilience following infection with SARS-CoV-2 or other pathogens.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This Perspective proposes that SARS-CoV-2 can trigger virus-induced senescence and amplify the senescence-associated secretory phenotype, linking pre-existing senescent cell burden to severe COVID-19 hyperinflammation. It argues that senolytic agents may offer an early therapeutic strategy and reviews supporting preclinical and early clinical evidence.

Key findings

  • SARS-CoV-2 infection can drive a full senescence response in susceptible cells, marked by p16INK4a, p21CIP1, H3K9me3, γH2A.X, lipofuscin, SA-β-gal activity, and SASP factors; such markers are elevated in airway and lung samples from patients with COVID-19 and correlate with disease severity.
  • SASP factors spread senescence to neighboring cells, prime macrophages toward an inflammatory state, and are linked to endothelial damage, NET formation, platelet activation, microthrombosis, and fibrosis; severity correlated with IL-6, SERPINA3, and D-dimer-based clotting activity, and patients with lung microthrombosis had higher SASP-typical factors.
  • Senolytics such as navitoclax, fisetin, and dasatinib plus quercetin killed virus-induced senescent cells in vitro; in animal models they reduced SASP cytokines to near-uninfected levels, improved lung pathology, and improved survival. In aged mice exposed to mouse pathogens, nearly all died within 2 weeks versus no mortality in younger mice, and senolytic treatment reduced mortality.
  • Two randomized trials of a bioavailable quercetin formulation in mild COVID-19 met their clinical endpoints; pooled analysis showed better avoidance of hospitalization, oxygen need, intensive care referral, and death. Fisetin trials in COVID-19 are ongoing.

Methods

  • This is a Perspective/narrative review, not a primary experimental study; it synthesizes cited in vitro, animal-model, patient histologic/transcriptomic, and clinical trial evidence.
  • The main analysis is conceptual: it develops a mechanistic model in which virus-induced senescence and SASP act as an amplifier of COVID-19 hyperinflammation, then evaluates senolytic strategies.
  • No new sample, dataset, or statistical analysis is reported by the authors; numerical results come from the cited studies.

Limitations

  • The authors state that a causal relationship between senescence extent and COVID-19 severity has not yet been demonstrated, that no single marker definitively identifies senescence, and that fixation of clinical samples prevents in situ SA-β-gal assays; they also call for more in vivo confirmation in senescence-compromised models.
  • The authors note debate over whether macrophages undergo classic senescence versus a senescence-like state, limited data on T cell senescence in COVID-19, and the need for further clinical studies to optimize senolytic regimens, timing, toxicity, and effects on viral clearance.
  • Evident from the text: as a Perspective, the evidence is largely correlative and preclinical, depends on cited studies, and some clinical support comes from early or small trials; proposed links to long COVID and autoimmunity remain speculative.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41577-022-00785-2

Cites

220 of 220 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

65 Not checked yet · 26 Own interpretation · 3 Partly supported · 1 No basis given · accuracy not yet measured

Verify all 150 references — free account

Show all 58 claims

  • Probably not a substantial claim. 4
  • It may state two separate claims as one. 35
37 of 37
  • The paper relies on this without support.

    The clinical severity of COVID-19 is largely determined by host factors.

    “The clinical severity of coronavirus disease 2019 (COVID-19) is largely determined by host factors.”
  • The paper relies on this without support.

    The most destructive phase of immune activation often occurs when viral mRNA is no longer detectable.

    “Interestingly, the most destructive phase of immune activation often occurs when the viral mRNA is no longer detectable.”
  • The paper relies on this without support.

    Elderly individuals have an increased proportion of pre-existing senescent cells in their tissues.

    “These effects are enhanced in elderly individuals who have an increased proportion of pre-existing senescent cells in their tissues.”
  • The paper relies on this without support.

    There is a significant unmet medical need for therapeutics to treat severe COVID-19 in unvaccinated or immunosuppressed individuals, elderly patients, and patients with chronic disease conditions.

    “there is still a significant unmet medical need for therapeutics to treat severe courses of disease in unvaccinated or immunosuppressed individuals as well as in elderly patients and patients with chronic disease conditions.”
  • The authors state this as an assumption.

    Viral entry and replication in vaccinated individuals would induce VIS and could trigger a cytokine storm that may lead to severe COVID-19.

    “The fact that viral entry and replication occur despite successful vaccination is interesting as VIS would be the assumed consequence and could trigger a cytokine storm potentially leading to severe COVID-19.”
5 of 5

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–220 of 220

Cited by

Sorted by citations

See all 153

Metadata

Authors
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S.
Affiliations
  • Johannes Kepler University of Linz (AT)
  • Mayo Clinic (US)
  • University of Minnesota (US)
Corresponding author
  • Schmitt, Clemens A.
  • Lee, Soyoung
Venue
Nature Reviews Immunology
Published
2022-10-05
Volume
23
Issue
4
Pages
251-263
ISSN
  • 1474-1733 (ISSN-L)
  • 1474-1741
OpenAlex
W4301595953
Cited by
153
References
220
Citations by year
2026: 28 · 2025: 34 · 2024: 44 · 2023: 45 · 2022: 2
FWCI
4.30
Type
journal article
Language
en
Open access
Locations
  • Nature reviews. Immunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
COVID-19 pandemic, SARS-CoV-2, cellular senescence, senescence-associated secretory phenotype, hyperinflammation, cytokine storm, extracellular matrix degradation, complement activation, coagulation, endothelial inflammation, fibrosis, microvascular thrombosis, paracrine senescence, senolytics, senolytic therapy, aging, elderly patients
MeSH terms
COVID-19, SARS-CoV-2, Aging, Humans, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review